Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horning, S. J.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horning, S. J.
Right arrow Articles by Rosenberg, S. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 3 (February), 2002: 630-637
© 2002 American Society for Clinical Oncology

Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin’s Disease: Mature Results of a Prospective Clinical Trial

By Sandra J. Horning, Richard T. Hoppe, Sheila Breslin, Nancy L. Bartlett, B. William Brown, Saul A. Rosenberg

From the Department of Medicine, Division of Medical Oncology, and Departments of Radiation Oncology and Health Research and Policy, Stanford University Medical Center, Stanford, CA.

Address reprint requests to Sandra J. Horning, MD, Division of Medical Oncology, Department of Medicine, 1000 Welch Rd, Suite 202, Palo Alto, CA 94304; email: sandra.horning{at}stanford.edu

PURPOSE: To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin’s disease.

PATIENTS AND METHODS: One hundred forty-two patients with stage III or IV or locally extensive mediastinal stage I or II Hodgkin’s disease received Stanford V chemotherapy for 12 weeks followed by 36-Gy RT to initial sites of bulky (>= 5 cm) or macroscopic splenic disease. Freedom from progression (FFP), overall survival (OS), and freedom from second relapse (FF2R) were determined using life-table estimates. Outcomes were analyzed according to the international prognostic score. Late effects of treatment were recorded in follow-up.

RESULTS: With a median follow-up of 5.4 years, the 5-year FFP was 89% and the OS was 96%. No patient progressed during treatment, and there were no treatment-related deaths. FFP was significantly superior among patients with a prognostic score of 0 to 2 compared with those with a score of 3 and higher (94% v 75%, P < .0001). No secondary leukemia was observed. To date, there have been 42 pregnancies after treatment. Among 16 patients who relapsed, the FF2R was 69% at 5 years.

CONCLUSION: These data confirm our preliminary report that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally extensive and advanced Hodgkin’s disease. It is most important to compare this approach with standard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial (E2496) to determine whether Stanford V with or without RT represents a therapeutic advance.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. J. Hoskin, L. Lowry, A. Horwich, A. Jack, B. Mead, B. W. Hancock, P. Smith, W. Qian, P. Patrick, B. Popova, et al.
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
J. Clin. Oncol., November 10, 2009; 27(32): 5390 - 5396.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. M. Edwards-Bennett, L. M. Jacks, C. H. Moskowitz, E. J. Wu, Z. Zhang, A. Noy, C. S. Portlock, D. J. Straus, A. D. Zelenetz, and J. Yahalom
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
Ann. Onc., September 16, 2009; (2009) mdp337v1.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, and A. Chauvenet
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Blood, September 3, 2009; 114(10): 2051 - 2059.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc., July 16, 2009; (2009) mdp271v1.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica, April 1, 2009; 94(4): 550 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Federico, S. Luminari, E. Iannitto, G. Polimeno, L. Marcheselli, A. Montanini, A. La Sala, F. Merli, C. Stelitano, S. Pozzi, et al.
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
J. Clin. Oncol., February 10, 2009; 27(5): 805 - 811.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Goodman, E. Riedel, V. Serrano, S. Gulati, C. H. Moskowitz, and J. Yahalom
Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma
J. Clin. Oncol., November 10, 2008; 26(32): 5240 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Metzger, S. M. Castellino, M. M. Hudson, S. N. Rai, S. C. Kaste, M. J. Krasin, L. E. Kun, C.-H. Pui, and S. C. Howard
Effect of Race on the Outcome of Pediatric Patients With Hodgkin's Lymphoma
J. Clin. Oncol., March 10, 2008; 26(8): 1282 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. De Bruin, J. Huisbrink, M. Hauptmann, M. A. Kuenen, G. M. Ouwens, M. B. van't Veer, B. M. P. Aleman, and F. E. van Leeuwen
Treatment-related risk factors for premature menopause following Hodgkin lymphoma
Blood, January 1, 2008; 111(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica, November 1, 2007; 92(11): 1533 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Advani, L. Maeda, P. Lavori, A. Quon, R. Hoppe, S. Breslin, S. A. Rosenberg, and S. J. Horning
Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease
J. Clin. Oncol., September 1, 2007; 25(25): 3902 - 3907.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. J. Dann, R. Bar-Shalom, A. Tamir, N. Haim, M. Ben-Shachar, I. Avivi, T. Zuckerman, M. Kirschbaum, O. Goor, D. Libster, et al.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Blood, February 1, 2007; 109(3): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Brusamolino and A. M. Carella
Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives
Haematologica, January 1, 2007; 92(1): 6 - 10.
[Full Text] [PDF]

Home page
 ASH-SAPHome page
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ng and P. Mauch
The impact of treatment on the risk of second malignancy after Hodgkin's disease
Ann. Onc., December 1, 2006; 17(12): 1727 - 1729.
[Full Text] [PDF]

Home page
 BloodHome page
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al.
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Blood, July 15, 2006; 108(2): 662 - 668.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. M. Noordijk, P. Carde, N. Dupouy, A. Hagenbeek, A. D.G. Krol, J. C. Kluin-Nelemans, U. Tirelli, M. Monconduit, J. Thomas, H. Eghbali, et al.
Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials
J. Clin. Oncol., July 1, 2006; 24(19): 3128 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. Foltz, K. W. Song, and J. M. Connors
Hodgkin's Lymphoma in Adolescents
J. Clin. Oncol., June 1, 2006; 24(16): 2520 - 2526.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al.
MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors
Clin. Cancer Res., January 15, 2006; 12(2): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. W.M. Johnson, J. A. Radford, M. H. Cullen, M. R. Sydes, J. Walewski, A. S. Jack, K. A. MacLennan, S. P. Stenning, S. Clawson, P. Smith, et al.
Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
J. Clin. Oncol., December 20, 2005; 23(36): 9208 - 9218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Carde
The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side?
J. Clin. Oncol., December 20, 2005; 23(36): 9058 - 9062.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Krasin, S. N. Rai, L. E. Kun, T. E. Merchant, M. L. Metzger, S. C. Kaste, S. C. Howard, and M. M. Hudson
Patterns of Treatment Failure in Pediatric and Young Adult Patients With Hodgkin's Disease: Local Disease Control With Combined-Modality Therapy
J. Clin. Oncol., November 20, 2005; 23(33): 8406 - 8413.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Martin, K. M. Ristow, T. M. Habermann, J. P. Colgan, T. E. Witzig, and S. M. Ansell
Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma
J. Clin. Oncol., October 20, 2005; 23(30): 7614 - 7620.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Connors
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6400 - 6408.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Engert, V. Ballova, H. Haverkamp, B. Pfistner, A. Josting, E. Duhmke, K. Muller-Hermelink, and V. Diehl
Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group
J. Clin. Oncol., August 1, 2005; 23(22): 5052 - 5060.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone
Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma
Clin. Cancer Res., March 15, 2005; 11(6): 2175 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Ballova, J.-U. Ruffer, H. Haverkamp, B. Pfistner, H. K. Muller-Hermelink, E. Duhmke, P. Worst, M. Wilhelmy, R. Naumann, M. Hentrich, et al.
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
Ann. Onc., January 1, 2005; 16(1): 124 - 131.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Connors
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma
Hematology, January 1, 2005; 2005(1): 239 - 244.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa
ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results
J. Clin. Oncol., July 15, 2004; 22(14): 2835 - 2841.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc., May 1, 2004; 15(5): 703 - 711.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Sieber, H. Tesch, B. Pfistner, U. Rueffer, U. Paulus, R. Munker, R. Hermann, G. Doelken, P. Koch, J. Oertel, et al.
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial
Ann. Onc., February 1, 2004; 15(2): 276 - 282.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Laskar, T. Gupta, S. Vimal, M.A. Muckaden, T.K. Saikia, S.K. Pai, K.N. Naresh, and K.A. Dinshaw
Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?
J. Clin. Oncol., January 1, 2004; 22(1): 62 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Hartmann, U. Rehwald, B. Salzberger, C. Franzen, M. Sieber, A. Wohrmann, and V. Diehl
BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection
Ann. Onc., October 1, 2003; 14(10): 1562 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Connors
Hodgkin's Lymphoma: The Hazards of Success
J. Clin. Oncol., September 15, 2003; 21(18): 3388 - 3390.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hohaus, G. Massini, F. D'Alo', F. Guidi, R. Putzulu, A. Scardocci, A. Rabi, A. L. Di Febo, M. T. Voso, and G. Leone
Association between Glutathione S-Transferase Genotypes and Hodgkin's Lymphoma Risk and Prognosis
Clin. Cancer Res., August 1, 2003; 9(9): 3435 - 3440.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan, U. Paulus, D. Hasenclever, H. Tesch, R. Herrmann, B. Dorken, H.-K. Muller-Hermelink, et al.
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
N. Engl. J. Med., June 12, 2003; 348(24): 2386 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Sieber, H. Bredenfeld, A. Josting, T. Reineke, U. Rueffer, T. Koch, R. Naumann, F. Boissevain, P. Koch, P. Worst, et al.
14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin's Lymphoma: Results of a Pilot Study of the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol., May 1, 2003; 21(9): 1734 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Spina, A. Re, E. Vaccher, J. Gabarre, and U. Tirelli
High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen
Ann. Onc., April 1, 2003; 14(4): 655 - 656.
[Full Text] [PDF]

Home page
 JCOHome page
V. Diehl
Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough!
J. Clin. Oncol., February 15, 2003; 21(4): 583 - 585.
[Full Text] [PDF]

Home page
 JCOHome page
D. B. Duggan, G. R. Petroni, J. L. Johnson, J. H. Glick, R. I. Fisher, J. M. Connors, G. P. Canellos, and B. A. Peterson
Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial
J. Clin. Oncol., February 15, 2003; 21(4): 607 - 614.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology, January 1, 2003; 2003(1): 225 - 247.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Spina, J. Gabarre, G. Rossi, M. Fasan, C. Schiantarelli, E. Nigra, M. Mena, A. Antinori, A. Ammassari, R. Talamini, et al.
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection
Blood, August 28, 2002; 100(6): 1984 - 1988.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. P. Canellos
New Treatments for Advanced Hodgkin's Disease: An Uphill Fight Beginning Close to the Top
J. Clin. Oncol., February 1, 2002; 20(3): 607 - 609.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online